US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Roche Holding Ltd

41.33

+0.25000.61%

Volume:2.67M

Turnover:110.57M

Market Cap:267.57B

PE:26.65

High:41.67

Open:41.65

Low:41.20

Close:41.08

Loading ...

Overview Company News Filings

Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk

This REIT's 7% Dividend Yield Looks Solid -- Barrons.com

Roche seeking U.S. tariff relief in direct talks with White House, Reuters says

Roche's Reiterated Outlook Looks Reassuring -- Market Talk

Roche's Results Are Solid -- Market Talk

Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update

Top Analyst Reports for Coca-Cola, Abbott & RTX

Roche's $50 Billion U.S. Investment Signals Trump's Tariff Strategy Is Working, AlphaValue Says -- Market Talk

Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ

Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update

Roche Sales Expected to Rise, Eye Drug Vabysmo in Focus -- Earnings Preview

Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars

Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk

EU Approval of Roche's Lymphoma Drug Is Good News But No Surprise -- Market Talk

Roche Holding AG Rises Thursday, Underperforms Market

Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk

Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update

Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RHHBY/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"Roche Holding Ltd","latestPrice":41.33,"timestamp":1746475200000,"preClose":41.08,"halted":0,"volume":2673237,"delay":15,"floatShares":6374000000,"shares":6474029800,"eps":1.550894,"marketStatus":"Pre-Mkt","change":0.25,"latestTime":"05-05 16:00:00 EDT Delay","open":41.65,"high":41.67,"low":41.2,"amount":110568364.83299999,"amplitude":0.011441,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1746538200000},"marketStatusCode":1,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":41.33,"volumeRatio":1.0901652728805187},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6374000000,"roa":"12.75%","roe":"26.47%","lyrEps":2.136203,"volumeRatio":1.0901652728805187,"shares":6474029800,"dividePrice":1.470116,"high":41.67,"amplitude":0.011441,"preClose":41.08,"low":41.2,"week52Low":30.03,"pbRate":"6.95","psRate":"3.54","week52High":44.31,"institutionHeld":0,"latestPrice":41.33,"eps":1.550894,"divideRate":0.03557,"volume":2673237,"delay":15,"ttmEps":1.550894,"open":41.65,"prevYearClose":34.88,"prevWeekClose":41.08,"prevMonthClose":40.77,"prevQuarterClose":41.15,"fiveDayClose":40.51,"twentyDayClose":37.65,"sixtyDayClose":39.61},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532860292","title":"Roche Shows Pipeline Progress But Near-Term Risks Remain -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2532860292","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532860292?lang=en_us&edition=fundamental","pubTime":"2025-05-02 14:25","pubTimestamp":1746167100,"startTime":"0","endTime":"0","summary":"0625 GMT - Concerns about Roche's upcoming clinical trial results persist despite improvements in its midstage pipeline over the past year, Berenberg analysts say in a note. The Swiss drugmaker's higher implemented threshold in assessing drug candidates should begin to shift the mix of its late-stage readouts toward higher return-on-investment assets, the analysts say. Berenberg analysts are less optimistic about Roche's key clinical results this year, seen as high-risk as they started before the company launched initiatives aimed at improving R&D decision-making. ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","RHHBY","PRGS","03165","BK4007","LU2065732104.USD"],"gpt_icon":0},{"id":"2530787163","title":"This REIT's 7% Dividend Yield Looks Solid -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2530787163","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2530787163?lang=en_us&edition=fundamental","pubTime":"2025-04-26 01:56","pubTimestamp":1745603760,"startTime":"0","endTime":"0","summary":"For dividend investors on the hunt for fat payouts, Alexandria Real Estate Equities' nearly 7% yield may provide an opportunity.Shares of the real-estate investment trust, which caters to the life-sciences industry, have languished in recent months, declining more than 35% to just under $76 from $116 a year ago. Blame factors like office space oversupply following and upheaval at the Food and Drug Administration.But the falling stock price has boosted Alexandria's dividend yield to 6.8%, an attractive proposition considering the company's solid financials and long-term prospects. Average yield on the Real Estate Select Sector SPDR, an exchange-traded fund focused on REITs, is just 3.4%.Wall Street's been down on the stock in large part because a Covid-era building boom has fizzled, leading to massive oversupply in health-related office space. In Boston, for instance, life-sciences office buildings have seen rental rates per square foot fall to $70 from $100, according to a recent repor","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","ARE","IE00BJT1NW94.SGD","LU0079474960.USD","LU1548497426.USD","LU2491050154.USD","LU0456855351.SGD","LU0471298777.SGD","REIT","LU0471298694.HKD","IE00BFTCPJ56.SGD","US3Y.BOND","US12M.BOND","LU2552382132.HKD","LU0672654240.SGD","LU1868836914.USD","MRNA","LU0256863811.USD","SG9999014880.SGD","BK4548","RHHBY","IE00B1BXHZ80.USD","LU2265009873.SGD","SG9999014914.USD","US7Y.BOND","US6M.BOND","LU1868837136.USD","SG9999015952.SGD","CFA.SI","LU1035775433.USD","LU2361045086.USD","LU0385154629.USD","US5Y.BOND","LU0114720955.EUR","LU1868837300.USD","LU1061106388.HKD","LU2750360997.AUD","LU1551013342.USD","LU0256863902.USD","US30Y.BOND","US10Y.BOND","US2Y.BOND","BK4194","LU2471134879.HKD","LU0106261372.USD","GB00BDT5M118.USD","LU0823416689.USD","LU1720051108.HKD","LU2468319806.SGD"],"gpt_icon":1},{"id":"2529893993","title":"Roche seeking U.S. tariff relief in direct talks with White House, Reuters says","url":"https://stock-news.laohu8.com/highlight/detail?id=2529893993","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529893993?lang=en_us&edition=fundamental","pubTime":"2025-04-24 21:56","pubTimestamp":1745502984,"startTime":"0","endTime":"0","summary":"Roche (RHHBY) is petitioning the Trump administration in direct talks for import tariff exemptions, arguing the products it ships into the U.S. are...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roche-seeking-u-s-tariff-relief-in-direct-talks-with-white-house-reuters-says?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roche-seeking-u-s-tariff-relief-in-direct-talks-with-white-house-reuters-says?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2529749786","title":"Roche's Reiterated Outlook Looks Reassuring -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529749786","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529749786?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:24","pubTimestamp":1745486640,"startTime":"0","endTime":"0","summary":"0924 GMT - Roche maintaining its 2025 targets, despite the current uncertain political environment from the U.S., reassures investors, Vontobel analyst Stefan Schneider says in a note. The Swiss pharma giant's key growth drivers continue to grow well, whereas new blockbuster eye drug Vabysmo missed consensus' expectations, he says. Shares are flat at 257.90 Swiss francs. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2529067151","title":"Roche's Results Are Solid -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529067151","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529067151?lang=en_us&edition=fundamental","pubTime":"2025-04-24 17:18","pubTimestamp":1745486280,"startTime":"0","endTime":"0","summary":"0918 GMT - Roche posted a solid first quarter, exceeding sales expectations and reaffirming its annual guidance despite the Trump administration tariff concerns, Barclays analysts say in a note. The Swiss pharma company's blockbuster drugs for multiple sclerosis Ocrevus and eye treatment Vabysmo missed Barclays' and market consensus, the analysts say. Investors will focus on diagnostics sales, hampered by pricing reforms in China, and Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues, they say. Shares fall 0.4% to 257.10 Swiss francs. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2529625872","title":"Roche Sales Gain on Boost From Key Drugs Amid U.S. Production Push -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2529625872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529625872?lang=en_us&edition=fundamental","pubTime":"2025-04-24 15:15","pubTimestamp":1745478900,"startTime":"0","endTime":"0","summary":"Roche posted higher-than-expected first-quarter sales, driven by robust demand for its key drugs, as the company takes active steps to preempt looming U.S. import tariffs.To strengthen its U.S. presence, Roche is building up inventory, ramping up production at three of its U.S. plants and relocating one manufacturing site to the U.S. through a technology transfer, its chief executive Thomas Schinecker said in a call with journalists.\"We've always kept intellectual property in the U.S. and continue to be a major tax payer in the U.S., so we haven't shifted our operations to countries like Ireland in the past,\" Schinecker said. \"There is an aim from the U.S. government that all the products that are needed by the U.S. are also produced in the U.S.,\" he said.Roche's U.S. incentives shouldn't come at the expense of manufacturing capacities in other countries and it is also looking to expand its footprint in China, he said. \"There is currently no plan to cut back on manufacturing in Europe ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2529038660","title":"Top Analyst Reports for Coca-Cola, Abbott & RTX","url":"https://stock-news.laohu8.com/highlight/detail?id=2529038660","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529038660?lang=en_us&edition=fundamental","pubTime":"2025-04-24 05:37","pubTimestamp":1745444220,"startTime":"0","endTime":"0","summary":"Wednesday, April 23, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including The Coca-Col","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-coca-cola-213700935.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CTAS","LU0912757837.SGD","IE00B42XCP33.USD","LU0787776722.HKD","LU2237443465.HKD","LU1064131342.USD","BK4587","LU1732800096.USD","LU2237957902.USD","FE","LU0302445910.USD","CNQ","ADI","03165","LU0553294199.USD","WDC","LU2125154935.USD","LOW","RTX","LU1061106388.HKD","ITIC","AMNF","AFRM","LU0708995401.HKD","LU2360032135.SGD","LU1035773651.USD","WRB","LU1988902786.USD","RHHBY","LU1929549753.HKD","ABT","JAZZ","LU2264538146.SGD","SG9999014567.USD","HTH","LU1069347547.HKD","LU1003077747.HKD","IE00BD6J9T35.USD","LU0642271901.SGD","LU0225283273.USD","IE00B5949003.HKD","IE0009355771.USD","LU0661504455.SGD","LU2552382058.USD","LU0098860793.USD","KO","BK4543"],"gpt_icon":1},{"id":"2529300917","title":"Roche's $50 Billion U.S. Investment Signals Trump's Tariff Strategy Is Working, AlphaValue Says -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2529300917","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529300917?lang=en_us&edition=fundamental","pubTime":"2025-04-22 21:03","pubTimestamp":1745326980,"startTime":"0","endTime":"0","summary":"1300 GMT - Roche's $50 billion U.S. investment signals that president Trump's pressure tactics amid tariffs prospects are proving effective, AlphaValue analysts say in a note. The Swiss pharma giant's five-year $50 billion pledge in U.S. manufacturing and R&D joins a growing trend of companies increasing investment in the country, they say. Roche shares fall 2% to 250.60 Swiss Francs. ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4588","03165","BK4600","BK4585","RHHBY","STRK","BK4007","BK4516","BK4595","BK4023"],"gpt_icon":1},{"id":"2529459379","title":"Drug Companies Step Up 'Make in America' Plans to Counter Tariffs -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2529459379","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529459379?lang=en_us&edition=fundamental","pubTime":"2025-04-22 18:51","pubTimestamp":1745319060,"startTime":"0","endTime":"0","summary":"Drugmakers Roche and Regeneron said they will spend billions of dollars to expand U.S. manufacturing, the latest pharmaceutical companies to commit to American production as new and future tariffs loom over medicines made abroad.Roche will invest $50 billion over five years, including in a new factory to make glucose-monitoring devices and a new plant for weight-loss drugs. The Swiss drugmaker said the investments will create 12,000 construction and other jobs.Regeneron, which makes drugs for skin and respiratory diseases, is doubling its U.S. manufacturing capacity in a new $3 billion, 10-year agreement with Fujifilm Diosynth Biotechnologies. Fujifilm's plant in Holly Springs, N.C., will make bulk drug material for Regeneron medicines.Chief Executive Leonard Schleifer said the deal would bolster the supply of Regeneron's medicines \"while generating economic growth and high-paying jobs for America itself.\" Regeneron also makes medicines in New York State and Limerick, Ireland.In additi","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","BK4007","03165"],"gpt_icon":0},{"id":"2529344328","title":"Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2529344328","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529344328?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:15","pubTimestamp":1745309700,"startTime":"0","endTime":"0","summary":"Swiss pharmaceutical giant Roche plans to invest $50 billion in the U.S. over the next five years, the latest major spending commitment by a big drugmaker as the industry faces President Trump's tariff threats.Pharma companies have in recent months set out plans to ramp up investments in the U.S. to boost local production and create jobs as the Trump administration prepares to impose tariffs on medicine imports--which have so far been exempted from such levies--and seeks to revive domestic manufacturing.Roche's move follows in the footsteps of a pledge by Swiss peer Novartis to spend $23 billion over the next five years to expand its footprint in the U.S. earlier this month. Meanwhile, last month Johnson & Johnson said it was increasing U.S. spending to more than $55 billion over the next four years, while Eli Lilly in February outlined plans for a $27 billion investment to build four new manufacturing plants in the country.The company currently has 15 R&D centers and 13 manufacturing ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom -- Update","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03165","RHHBY","BK4007"],"gpt_icon":0},{"id":"2529034436","title":"Roche Sales Expected to Rise, Eye Drug Vabysmo in Focus -- Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2529034436","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529034436?lang=en_us&edition=fundamental","pubTime":"2025-04-22 16:15","pubTimestamp":1745309700,"startTime":"0","endTime":"0","summary":"Roche is scheduled to report results for the first quarter on Thursday. Here is what you need to know.SALES FORECAST: The group's sales should come to 15.33 billion Swiss francs , according to consensus estimates of 14 analysts compiled by Visible Alpha. This compares with 14.39 billion francs the year before.The stock fell 1.1% since the start of 2025 but is up 15% over the past year.--Beyond tariffs, investor attention centers around key growth drivers and the potential for late-stage pipeline readouts, UBS analysts said. Investors will look at commentary on blockbuster eye drug Vabysmo's sales performance, which could slow down in the U.S. due to potential Medicare funding issues affecting patients, UBS and Barclays analysts said.Both brokers expect that solid growth trends for multiple sclerosis drug Ocrevus and hemophilia injection Hemlibra have continued in the first quarter. Key late-stage trials include astegolimab in chronic obstructive pulmonary disease, early breast cancer e","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY"],"gpt_icon":0},{"id":"2528723115","title":"Eli Lilly's weight loss pill could be just as good as Ozempic — and the stock soars","url":"https://stock-news.laohu8.com/highlight/detail?id=2528723115","media":"Quartz","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528723115?lang=en_us&edition=fundamental","pubTime":"2025-04-17 23:20","pubTimestamp":1744903245,"startTime":"0","endTime":"0","summary":"The first GLP-1 pill could be in medicine cabinets sooner than expected.Eli Lilly  announced Thursday that its daily obesity pill, orforglipron, met company goals in the first of several late-stage trials — helping patients with Type 2 diabetes lower their blood sugar while causing weight loss. The results were comparable with other GLP-1 injections on the market, such as Ozempic and Mounjaro.Orforglipron could give Lilly a key advantage over other pharmaceutical giants in the GLP-1 realm. Lilly’s stock was up 11% in premarket trading. Novo Nordisk , which makes Ozempic, was down 6%.The results are pivotal: While the GLP-1 class of medication has become a blockbuster on the market , they’re expensive, must be injected, and need to be kept refrigerated. A pill version would be a more convenient option that could be much more widely used.The study measured weight loss as a secondary goal. Patients who received orforglipron also reported weight loss — up to 16 pounds without","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/eli-lillys-weight-loss-pill-152045475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1551013342.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","RHHBY","SG9999015952.SGD","SG9999014906.USD","LU0114720955.EUR","LU2237438978.USD","LU0109391861.USD","LU1868836914.USD","LU0106261372.USD","LU1127390331.HKD","LU1720051017.SGD","IE00B2B36J28.USD","LU0820561909.HKD","LU0289739699.SGD","LU2361044865.SGD","LU1267930730.SGD","LU0320765059.SGD","BK4588","SGXZ81514606.USD","IE00BKVL7J92.USD","CDC","LU0466842654.USD","LU2361045086.USD","LU2357305700.SGD","LU2602419157.SGD","LU0882574139.USD","LU0203201768.USD","LU0122379950.USD","LU1548497426.USD","LU0006306889.USD","LU1868837300.USD","NVO","LU0823416689.USD","03165","LU2750360997.AUD","LU0256863902.USD","IE0004445239.USD","LLY","GB00BDT5M118.USD","LU1366192091.USD","LU0471298694.HKD","LU0354030438.USD","LU1280957306.USD","LU1917777945.USD","LU2237443549.SGD","SG9999017495.SGD","LU2750360641.GBP","SG9999018857.SGD"],"gpt_icon":1},{"id":"2528474479","title":"Pharma Stock Roundup: J&J's Q1 Results, PFE's Obesity Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2528474479","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528474479?lang=en_us&edition=fundamental","pubTime":"2025-04-17 21:15","pubTimestamp":1744895700,"startTime":"0","endTime":"0","summary":"J&J JNJ began the earnings season for the drug and biotech sector this week. Pfizer PFE announced the discontinuation of its danuglipron weight loss pill program. The European Commission granted marketing authorization for the expanded use of Roche’s RHHBY cancer drug, Columvi. Sanofi SNY provided an update on its respiratory pipeline.Here's a recap of the week’s most important stories.J&J beat first-quarter estimates for both earnings and sales. Adjusted earnings of $2.77 per share rose 2.2% from the year-ago period. Sales of $21.89 billion rose 2.4% from the year-ago quarter. Innovative Medicines segment sales rose 2.3% year over year to $13.87 billion. MedTech segment sales came in at $8.02 billion, up 2.5% from the year-ago period.The U.S. Centers for Disease Control and Prevention’s  Advisory Committee on Immunization Practices recommended the expanded use of Pfizer and GSK’s respiratory syncytial virus  vaccines, Abrysvo and Arexvy, respectively, in adults aged 50 to 59 at increa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-j-js-131500764.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2347655156.SGD","SG9999013999.USD","JNJ","03165","LU2430703095.HKD","LU1778281490.HKD","LU1066051225.USD","IE00BN8TJ469.HKD","IE00BFXG1179.USD","BK4581","PFE","LU0058720904.USD","LU0985320562.USD","LU1032466523.USD","SG9999001440.SGD","SG9999003800.SGD","BK4568","IE00BDGV0183.EUR","LU1244550494.USD","LU1162221912.USD","IE0002141913.USD","LU2129689605.HKD","LU0098860793.USD","LU2505996509.AUD","LU2430703178.SGD","LU1066051811.HKD","LU0122379950.USD","SGXZ57979304.SGD","BK4550","LU2430703251.USD","LU1718418525.SGD","SNY","LU1244550221.USD","LU0795875169.SGD","IE00B19Z3581.USD","CDC","IE00B19Z3B42.SGD","IE00BGHQF631.EUR","RHHBY","LU0345769128.USD","IE00BVYPNV92.GBP","LU1585245621.USD","LU0203345920.USD","IE00BBT3K403.USD","SG9999001176.USD","LU0985481810.HKD","IE00BSNM7G36.USD","LU0170899867.USD","LU0792757196.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2527217592","title":"SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2527217592","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527217592?lang=en_us&edition=fundamental","pubTime":"2025-04-16 19:32","pubTimestamp":1744803120,"startTime":"0","endTime":"0","summary":"Sarepta Therapeutics SRPT announced updates from its clinical programs, which focus on targeting different subtypes of limb-girdle muscular dystrophy , a group of rare genetic disorders marked by progressive muscle weakness.Following positive FDA feedback, the company is advancing a fourth LGMD program to clinical development. Sarepta will soon start screening and dosing patients in the first-in-human clinical SRP-9005-101  study, to evaluate its investigational gene therapy SRP-9005 for LGMD type 2C/R5 .SRPT also announced completion of enrollment and dosing in the phase I proof-of-concept SRP-9004-102  study, which is evaluating SRP-9004 in patients with LGMD type 2D/R3 .The company also reiterated its plans to report data from the late-stage EMERGENE study, evaluating SRP-9003 in patients with LGMD type 2E/R4 , by first-half 2025. This study’s primary endpoint is the biomarker expression of the beta-sarcoglycan protein, whose absence is the sole cause of the disease. Following a pre","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/srpt-provides-pipeline-updates-rare-113200363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1559883803.SGD","ANIP","IE0002141913.USD","03165","RHHBY","IE0009355771.USD","IE00BFTCPJ56.SGD","CTMX","BK4585","LU0566484027.USD","SRPT","BK4139","BK4007","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","IE00B2B36J28.USD"],"gpt_icon":0},{"id":"2527467116","title":"U.S Pharma Import Probe Clouds Clarity for EU Companies -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527467116","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527467116?lang=en_us&edition=fundamental","pubTime":"2025-04-15 17:55","pubTimestamp":1744710900,"startTime":"0","endTime":"0","summary":"0955 GMT - A U.S. investigation into pharmaceutical imports and potential tariffs in the coming months will likely limit clarity from pharma companies during their 1Q results, Barclays analysts say in a note. The investigation, initiated April 1, aims to assess the national security implications of pharmaceutical imports, including finished generics, nongenerics and active pharmaceutical ingredients, and has to be finalized in around nine months. \"With Pharma having been excluded from the initial reciprocal tariffs and it being our house view that some sort of Commerce Department investigation being required for these sectoral tariffs, this isn't too surprising but at least provides some timing framing,\" they say. Barclays analysts estimate that AstraZeneca, Roche and Grifols appear most insulated, whereas GSK and Sandoz look most exposed to a potential tariff risk. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","LU2462157665.USD","BK4588","RHHBY","BK4007","03165","LU1829250122.USD","BK4156","LU0109394709.USD","GSK.UK","LU0320765992.SGD","BK4568","BK4139","BK4585","LU0889565916.HKD","GRFS","LU2236285917.USD","AZN","GSK","LU2456880835.USD","BK4532"],"gpt_icon":0},{"id":"2527183872","title":"EU Approval of Roche's Lymphoma Drug Is Good News But No Surprise -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2527183872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527183872?lang=en_us&edition=fundamental","pubTime":"2025-04-14 16:57","pubTimestamp":1744621020,"startTime":"0","endTime":"0","summary":"0857 GMT - Swiss pharma giant Roche's lymphoma drug Columvi getting EU approval as a second-line treatment is positive but expected, Vontobel analyst Stefan Schneider says in a note. Columvi is the first treatment for patients with relapsed or refractory diffuse B-cell lymphoma in Europe who didn't respond to initial treatment. Shares rise 2.5% to 250 Swiss francs.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY","BK4156"],"gpt_icon":0},{"id":"2526513750","title":"Roche Holding AG Rises Thursday, Underperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2526513750","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526513750?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:17","pubTimestamp":1744301820,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Roche Holding AG  rose 3.2% to CHF243.00 Thursday on what proved to be an overall positive trading session for the stock market, with the Swiss SMI Index  rising 3.3% to 11,244.59.Roche Holding AG closed CHF70.80 short of its 52-week high of CHF313.80, which the company achieved on March 12, 2025.Trading volume was 1,892,499, compared to the 50-day average trading volume of 1,455,718.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG"],"gpt_icon":0},{"id":"2526899425","title":"Pharma Stocks Surge After Trump's Tariff Pause -- Market Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2526899425","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526899425?lang=en_us&edition=fundamental","pubTime":"2025-04-10 15:36","pubTimestamp":1744270560,"startTime":"0","endTime":"0","summary":"0736 GMT - European pharma stocks jump at Thursday's market open, mirroring broader market gains, after U.S. President Trump announced a 90-day pause on so-called reciprocal tariffs. The Stoxx 600 health index surges around 7.2%, outpacing the wider Stoxx 600's 1.2% rise. While pharmaceuticals have so far been spared, Trump reiterated on Tuesday that tariffs on imported medicines remain a possibility. ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","SNY","03165","NVS","AZN","GSK.UK","LU0320765489.SGD","GSK","LU2456880835.USD","RHHBY","LU0889565916.HKD","BK4532","IE00B2B36J28.USD","LU2462157665.USD","LU0208291251.USD","BK4568","LU2236285917.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4585","LU0109394709.USD","BK4007","BK4578","BK4588","IE00BJT1NW94.SGD","BAYRY","IE00BJJMRZ35.SGD","LU0211331839.USD","IE0009355771.USD","LU2417539215.USD","IE00BFXG1179.USD","LU0070302665.USD","IE00B4R5TH58.HKD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2526963233","title":"Pharma Stocks Slide Further After Trump Reiterates Tariff Threats on Drugs -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2526963233","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526963233?lang=en_us&edition=fundamental","pubTime":"2025-04-09 23:03","pubTimestamp":1744210980,"startTime":"0","endTime":"0","summary":"Pharmaceutical stocks sank lower Wednesday after President Trump doubled down on his promise to slap tariffs on a long-exempt industry, causing market turmoil globally.The Dow Jones U.S. Pharmaceuticals Index slipped 3.7% to 768.75 Wednesday morning, at one point hitting a 52-week low of 766.61. AbbVie shares fell 5.9% to $165.34, while Eli Lilly, Merck and Pfizer all declined about 3%.In European morning trade, the Stoxx Europe 600 Health Care index--which is heavily dominated by Europe's six largest pharma companies--dropped 3.1% Wednesday, also touching a year low earlier in the session.Switzerland's Roche and Novartis, the U.K.'s AstraZeneca, Denmark's Novo Nordisk and France's Sanofi were all down more than 5% in morning trade. Japan's Daiichi Sankyo and Takeda Pharmaceutical retreated 6% and 4.7%, respectively, while Australia's CSL shed 5%.The pharma sector had been spared last week from Trump's sweeping tariff plan, which kicked in Wednesday, and drug companies have been exempt","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443382.USD","LU0882574139.USD","LU1066051811.HKD","LU1804176565.USD","SG9999002224.SGD","SNY","IE00BVYPNV92.GBP","LU2129689605.HKD","LU0265550359.USD","LU0708995401.HKD","LU2347655156.SGD","LU2552382132.HKD","NVS","LU2462157665.USD","LU0385154629.USD","PFE","IE00B19Z3581.USD","LU1003077747.HKD","CSL.AU","SG9999001440.SGD","LU1720051108.HKD","AZN","LU0029864427.USD","LU0943347566.SGD","LU0070302665.USD","LU0553294199.USD","DSNKY","MRK","TAK","LU2602419157.SGD","LU1983299246.USD","NVO","LU0061475181.USD","03165","LU1035775433.USD","LU0208291251.USD","LU1496350171.SGD","BK7511","LU1366192091.USD","LLY","IE00B3PB1722.GBP","IE00BJLML261.HKD","IE00BZ1G4Q59.USD","ABBV","RHHBY","SG9999015945.SGD","LU1829250122.USD","BK7501","LU0158827948.USD","LU0109391861.USD"],"gpt_icon":1},{"id":"2526356596","title":"Pharma Stocks Drop After Trump Threatens Tariffs on Medicines -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356596","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356596?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:17","pubTimestamp":1744193820,"startTime":"0","endTime":"0","summary":"Stocks in drugmakers sold off globally after President Trump said tariffs on pharmaceutical imports will be unveiled shortly, signaling the industry could be next in line amid a trade war that is causing market turmoil.-- Switzerland's Roche and Novartis, the U.K.'s AstraZeneca and GSK and France's Sanofi were all down 5% or more in European midday trade.-- Japan's Daiichi Sankyo and Takeda Pharmaceutical closed 6% and 4.7% lower, respectively.-- In U.S. premarket trading, Eli Lilly, Merck and Pfizer all fell at least 1%.The drug sector was spared from Trump's sweeping tariff plan that kicked in today, but the president's remarks at a Tuesday dinner with House Republicans suggested levies could come very shortly.This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL .","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2417539215.USD","03165","LU2236285917.USD","SG9999003800.SGD","LU1894683348.USD","SG9999002232.USD","LU0070302665.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE0002270589.USD","GSK.UK","IE00B19Z3581.USD","LU0289739699.SGD","SG9999001176.USD","IE00B19Z3B42.SGD","BK4588","LU0170899867.USD","BK4007","IE00BJJMRZ35.SGD","LU1066053197.SGD","LU0225284248.USD","LU1023059063.AUD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE00BFXG1179.USD","LU2456880835.USD","BK4534","SG9999013999.USD","LU2462157665.USD","GSK","MDCO","SNY","LU0234572021.USD","BK4599","LU0208291251.USD","LU0889565916.HKD","RHHBY","AZN","BK4532","LU1829250122.USD","BK4533","NVS","LU1894683264.USD","SG9999011175.SGD","BK4568","IE00BLSP4239.USD","LU0321505868.SGD","LU0225771236.USD","IE0009355771.USD"],"gpt_icon":1}],"pageSize":20,"totalPage":7,"pageCount":1,"totalSize":127,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"Pre-Market","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.125,"hold":0.75,"sell":0,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.75,"analysts":8,"updateTime":1746072000000}}}